复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 11-09 16:08:05

16.860

-0.360

-2.09%

最高17.450	最低16.780	成交量203.74万
今开17.450	昨收17.220	日振幅3.89%
总市值445.27亿	流通市值88.18亿	总股本26.41亿
成交额3,461万	换手率0.39%	流通股本5.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.86,"timestamp":1794211685005,"preClose":17.22,"halted":0,"volume":2037397,"delay":0,"changeRate":-0.020905923344947702,"floatShares":523000000,"shares":2641000000,"eps":1.4926964186290885,"marketStatus":"未开盘","change":-0.36,"latestTime":"11-09 16:08:05","open":17.45,"high":17.45,"low":16.78,"amount":34608700,"amplitude":0.038908,"askPrice":16.86,"askSize":5500,"bidPrice":16.83,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":1.5633961627026136,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":17.22,"dividendRate":0.027225,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":0.544446,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.11,"timestamp":1794207600000,"preClose":23.58,"halted":0,"volume":15274400,"delay":0,"premium":"-37.93"}},"requestUrl":"/m/hq/s/02196/wiki","defaultTab":"wiki","newsList":[{"id":"2682280545","title":"贝莱德在复星医药的H股好仓比例上升0.65%至7.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682280545","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682280545?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:21","pubTimestamp":1794216117,"startTime":"0","endTime":"0","summary":"21财经11月9日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在复星医药的H股好仓（L）比例于11月4日从6.51%上升至7.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926324794.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926324794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK0183","BK0028","BK0012","BK1593","600196","02196","BK0175","BK0188","BK0239","BK1515","BK0060","BK0187","BK0196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160821167","title":"复星医药：贝莱德增持，好仓比例升至7.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160821167","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160821167?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:14","pubTimestamp":1794215694,"startTime":"0","endTime":"0","summary":"贝莱德于2026年11月4日通过取得股份的保证权益的方式在场外增持复星医药（02196）H股354.17万股，该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有复星医药好仓3595.67万，占比6.51%；增持后持股量为3949.84万，好仓比例升至7.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681412817","title":"进博观察｜首发首展扎堆！西门子医疗、GE医疗、美敦力同台竞技，全球医疗器械巨头加码中国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2681412817","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681412817?lang=zh_cn&edition=full","pubTime":"2026-11-07 21:13","pubTimestamp":1794057231,"startTime":"0","endTime":"0","summary":"第九届进博会，“最卷展区”医疗器械及医药保健展区再度火爆。12家世界500强制药企业到场，全球排名前20的药企来了16家，全球前三大医学影像企业和前三大放疗设备企业悉数参展，展台面积亦创下历届之最。西门子医疗、GE医疗、美敦力、复星医药等医疗器械巨头展台人头攒动，“全球首发”“中国首展”“中国首发”的标识被挂在最显眼的位置。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611073925543798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611073925543798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0158827948.USD","LU2028103732.USD","BK0239","IE00BGHQF631.EUR","LU0265550359.USD","LU0122379950.USD","LU0310800965.SGD","LU0128525689.USD","LU0211326839.USD","LU0976567544.SGD","BK4082","BK0175","BK0028","LU2089984988.USD","LU1506573853.SGD","LU1236620750.USD","MDT","LU1989771016.USD","LU2089284900.SGD","IE00B3PB1722.GBP","BK0096","600196","LU1291159041.SGD","LU1116320737.USD","BK4566","LU1989764748.USD","BK0012","LU1061106388.HKD","LU2112291526.USD","BK0196","BK0060","IE00BQXX3D17.EUR","BK4588","IE000M9KFDE8.USD","LU0070302665.USD","BK4585","LU2271345857.HKD","LU0314106906.USD","LU1023059063.AUD","IE00BFXG1179.USD","LU1267930227.SGD","LU2023251221.USD","LU0265550946.USD","BK0187","IE00BVYPNV92.GBP","LU1244550577.SGD","IE00BQXX3C00.GBP","IE00B42XCP33.USD","LU0072461881.USD","LU0211331839.USD","BK0183","LU0496365809.HKD","IE00BVYPNW00.USD","LU1989764664.SGD","LU1983299246.USD","LU0106261372.USD","LU0162691827.USD","LU1116320901.HKD","LU0432979614.USD","LU2089283258.USD","LU0006306889.USD","LU2111349929.HKD","LU0211326755.USD","IE00BDGV0183.EUR","LU0320765489.SGD","LU0208291251.USD","02196","LU1236620834.HKD","LU0052756011.USD","LU1571399168.USD","LU2468319806.SGD","BK4533","LU1057294990.SGD","LU1244550221.USD","IE00B3T34201.USD","BK0188","LU1244550494.USD","LU0158827781.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090186","title":"【券商聚焦】国泰海通证券：美护板块估值及持仓均处底位，看好成长型标的修复弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090186","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681090186?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:06","pubTimestamp":1793840817,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券研究指，26Q3美护板块收入/归母/扣非同比+10%/-36%/-29%，细分板块中个护稳健，美妆高端好于大众，医美下游好于上游，当前板块估值及持仓均处底位，看好成长型标的修复弹性。该机构推荐：1）基本面强劲的高成长标的；2）估值较低的龙头标的；3）预期低位、后续边际有望改善的标的。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1564","SG9999004311.SGD","BK1215","BK0276","BK1600","LU0502904849.HKD","BK1207","BK1100","BK0201","601211","HK0000165453.HKD","06699","BK1191","02145","02138","BK1587","BK1515","01830","02367","BK1511","KCE","LU2488822045.USD","BK0184","01696","02196","01530","LU0455707207.USD","BK1583","02373","BK0188","BK1161","LU2242644610.SGD","BK0028","02611","BK0183","BK1147","BK1593","00460","161027","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680058197","title":"复星医药（600196）披露H股购回进展，11月4日股价上涨1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680058197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680058197?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:35","pubTimestamp":1793792137,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘，复星医药报收于23.27元，较前一交易日上涨1.13%，最新总市值为621.41亿元。公司于近日披露H股购回进展：上海复星医药(集团)股份有限公司于2026年11月3日在香港联交所购回1,084,000股H股股份，每股购回价介于港币16.64至17.00元之间，总代价为港币18,363,195元。本次购回股份拟持作库存股份。购回后库存股份总数为28,937,500股。此次购回根据2026年6月16日通过的购回授权进行，占该日已发行股份的3.32%。购回后30日内不得发行新股或出售库存股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400036153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0096","BK0239","BK0183","BK0188","02196","600196","BK1593","BK0196","BK1191","BK0012","BK1515","BK0060","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182243054","title":"复星医药FXS6837启动中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1182243054","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182243054?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:51","pubTimestamp":1793785914,"startTime":"0","endTime":"0","summary":"2026年11月4日，复星医药披露，其控股子公司上海复星医药产业发展有限公司已在中国境内启动用于治疗阵发性睡眠性血红蛋白尿症的FXS6837胶囊III期临床试验。除PNH以外，FXS6837用于治疗IgA肾病等补体异常激活相关肾小球疾病的IIb期临床试验目前正在中国境内开展。公司提示，FXS6837须在中国境内完成相关临床试验并经国家药品审评部门审批通过后方可上市，研发及审批过程存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159394575","title":"复星医药：控股子公司自研IL1RAP单抗HLX109获澳大利亚首个临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1159394575","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159394575?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:45","pubTimestamp":1793785555,"startTime":"0","endTime":"0","summary":"2026年11月4日，复星医药公告称，其控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的HLX109注射液用于泛发性脓疱型银屑病治疗的I期临床试验方案，已获澳大利亚人类研究伦理委员会批准并完成在澳大利亚药品管理局的备案。这是HLX109在全球范围内取得的首个临床试验许可。复宏汉霖计划在条件具备后于澳大利亚开展相应临床研究。截至2026年9月，复星医药及其控股子公司针对HLX109累计研发投入约0.34亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173663438","title":"复星医药参设杭州基金迎股权调整　博腾股份受让3,000万元认缴份额","url":"https://stock-news.laohu8.com/highlight/detail?id=1173663438","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173663438?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:45","pubTimestamp":1793785553,"startTime":"0","endTime":"0","summary":"2026年11月4日，上海复星医药（集团）股份有限公司公告称，其控股企业苏州君明致远创业投资合伙企业参与设立的杭州复曜星启成果转化创业投资合伙企业发生有限合伙人份额转让。复星医药表示，本次份额转让不影响其在杭州基金中的34.75%认缴比例，亦不会对公司财务状况及经营成果产生重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680035097","title":"复星医药(600196.SH)子公司HLX109注射液获准于澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2680035097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680035097?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:08","pubTimestamp":1793783301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX109注射液(即靶向IL1RAP的单克隆抗体)用于泛发性脓疱型银屑病治疗的I期临床试验方案获相关人类研究伦理委员会批准、并通过澳大利亚药品管理局备案，系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0239","BK0096","BK1191","PSYK","BK0175","BK0187","BK0183","02196","IBBQ","BK1593","BK0012","BK0028","MDTX","BMED","BK1515","600196","BK0188","IBBJ","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680103829","title":"港股异动 | 复星国际(00656)收涨近5% 旗下多家公司业绩亮眼 复星医药前三季扣非净利润增超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680103829","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680103829?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:21","pubTimestamp":1793780467,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星国际收涨近5%。截至收盘，涨4.74%，报4.64港元，成交额3066.82万港元。消息面上，复星国际旗下多家上市公司近日公布业绩，复星医药前三季度营业收入304.63亿元，同比增长3.64%；归母净利润26.67亿元，同比增长5.71%；扣非归母净利润17.06亿元，同比增长8.42%。此外，复星国际旗下豫园股份前三季度营收229.81亿元，净利润1.68亿元；复星高科前三季度归母利润5.05亿元，同比扭亏为盈。公司在“聚焦主业，瘦身健体”的规划下，2026年继续推进8424战略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","600196","00656","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680747336","title":"复星医药（600196）披露H股股份购回公告，11月03日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680747336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680747336?lang=zh_cn&edition=full","pubTime":"2026-11-03 18:58","pubTimestamp":1793703498,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，复星医药报收于23.01元，较前一交易日上涨1.01%，最新总市值为614.47亿元。公司于2026年11月3日披露H股翌日披露报表。公告显示，上海复星医药(集团)股份有限公司于2026年11月2日在港交所披露，当日购回200万股H股股份，每股购回价介乎16.32港元至16.85港元，总代价为33,323,710港元。本次购回股份拟全部持作库存股份。此次购回后30日内不得发行新股或出售库存股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300036608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1593","BK0060","BK0188","BK1515","BK0175","BK0183","BK0187","02196","BK1191","BK0096","BK0239","600196","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116375914","title":"复星医药11月3日回购108.40万股，斥资约1,836.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116375914","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116375914?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:13","pubTimestamp":1793697204,"startTime":"0","endTime":"0","summary":"复星医药于2026年11月3日公告，公司在香港联交所回购普通股合计1,084,000股，占回购前公司已发行股份总数约0.21%。本次回购价格区间介乎每股16.64港元至17.00港元，合计耗资约18,363,195港元。公司回购授权于2026年6月16日获股东大会批准，允许回购总量为54,097,150股，截至目前，公司已根据回购授权累计回购17,968,500股，占获授权当日已发行股份总数的3.32%。公司同时确认，本次回购过程遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司董事陈玉卿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复星医药11月3日回购108.40万股，斥资约1,836.32万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680730190","title":"复星医药(02196.HK)：袁方兵辞任副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2680730190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680730190?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:37","pubTimestamp":1793612270,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","02196","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104086293","title":"复星医药：11月2日回购200万股，耗资约3332.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104086293","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104086293?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:34","pubTimestamp":1793612046,"startTime":"0","endTime":"0","summary":"复星医药（02196）于2026年11月2日回购2,000,000股，占当日回购前公司已发行股本约0.38%。回购价格介乎每股16.32港元至16.85港元，支付总金额约3,332.37万港元。\n回购完成后，公司已发行股本为524,087,000股，库藏股数量增至27,853,500股。该次回购基于2026年6月16日通过的购回授权，截至目前合计已购回16,884,500股。公司确认相关程序符合香港联交所上市规则及其他法律法规要求。\n本公告由公司董事陈玉卿签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复星医药：11月2日回购200万股，耗资约3332.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680737463","title":"复星医药(02196.HK)11月2日耗资约3332.37万港元回购200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680737463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680737463?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:20","pubTimestamp":1793611208,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02196","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680723734","title":"复星医药：袁方兵辞去副总裁职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2680723734","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680723734?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:30","pubTimestamp":1793608200,"startTime":"0","endTime":"0","summary":"南财智讯11月2日电，复星医药公告，因个人原因，袁方兵先生向董事会辞去公司副总裁职务，其辞任于送达董事会时生效。辞职后，袁方兵不再在公司及其控股子公司任职，不存在未履行完毕的公开承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611023918742420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611023918742420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK1593","BK0239","BK1191","BK1515","BK0183","BK0012","BK0188","600196","BK0187","BK0175","BK0060","BK0096","BK0196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196750101","title":"复星医药公布2026年10月股份变动月报，H股合计回购352万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1196750101","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196750101?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:26","pubTimestamp":1793608007,"startTime":"0","endTime":"0","summary":"复星医药于2026年11月2日披露2026年10月股份变动月报。根据公告，公司于本月末的法定注册股本合计人民币2,670,429,325元，其中A股注册股本为人民币2,118,488,825元，H股注册股本为人民币551,940,500元。与上月相比，注册股本无新增或减少，保持整体稳定。上述变化主要源于公司在10月28日至10月30日期间通过场内回购合计3,520,000股H股，价格区间为每股16.20港元至16.71港元，所有回购的股份目前均持作库藏，暂未注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称，2026年欧洲内科肿瘤学会 中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指，中国医药具有“创新升级+供应链韧性”优势，2025年创新药海外授权首付款大幅超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU2476274308.USD","LU1969619763.USD","BK1515","LU0540923850.HKD","SG9999004311.SGD","601066","IE00B5MMRT66.SGD","BK0188","03069","LU2476274720.SGD","01530","LU2399975544.HKD","03933","09926","01789","LU0634319403.HKD","BK1610","LU0228659784.USD","LU0348825331.USD","LU0588546209.SGD","01099","BK1617","600056","BK1161","LU0348783233.USD","LU0348767384.USD","09688","LU0417516902.SGD","LU0348766576.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU0307460666.USD","02367","LU1251922891.USD","KCE","LU2488822045.USD","SG9999014674.SGD","BK0028","02268","KURE","02196","06821","LU1720050803.USD","02228","BK1141","LU0561508036.HKD","06160","BK1207","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680783187","title":"股市必读：复星医药新发布《复星医药H股公告-翌日披露报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680783187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680783187?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:44","pubTimestamp":1793576654,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，复星医药报收于22.66元，上涨1.57%，换手率0.94%，成交量19.96万手，成交额4.51亿元。本次购回后，已发行股份总数为551,940,500股，其中已发行H股为526,407,000股，库存股增至25,533,500股。复星医药H股公告-翌日披露报表上海复星医药(集团)股份有限公司于2026年10月30日购回320,000股H股股份，每股购回价介乎港币16.09至16.50元，合计支付金额港币5,253,615元。本次购回股份拟持作库存股份。若涉及重大合作，公司将根据股票上市地规则履行相应的信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","02196","BK1191","BK1515","BK0012","BK0183","BK0096","BK1593","BK0028","BK0239","BK0196","BK0187","BK0188","600196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679463062","title":"复星医药（600196）2026年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679463062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679463062?lang=zh_cn&edition=full","pubTime":"2026-10-30 23:56","pubTimestamp":1793375764,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期复星医药发布2026年三季报。截至本报告期末，公司营业总收入304.63亿元，同比上升3.64%，归母净利润26.67亿元，同比上升5.71%。按单季度数据看，第三季度营业总收入100.21亿元，同比上升1.44%，第三季度归母净利润9.46亿元，同比上升15.18%。本报告期复星医药盈利能力上升，毛利率同比增幅3.13%，净利率同比增幅2.52%。本文数据来源于复星医药2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000059132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":-0.0565},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0704},{"period":"1year","weight":-0.2275},{"period":"ytd","weight":-0.1141}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.03393},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.040558},{"month":9,"riseRate":0.5,"avgChangeRate":0.021862},{"month":10,"riseRate":0.428571,"avgChangeRate":0.011176},{"month":11,"riseRate":0.466667,"avgChangeRate":0.033757},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}